Full Text
CN3 60-MONTH DATA FROM IRIS USED TO UPDATE ESTIMATES OF SURVIVAL AND COST-EFFECTIVENESS OF FIRST-LINE IMATINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA

Abstract

Authors

SD Reed KJ Anstrom Y Li KA Schulman

Back to Volume 10, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×